Scholarlink

Objective <p>This study aims to comprehensively analyze the role of metabolic signatures in rheumatoid arthritis (RA).</p> Methods <p>A total of 599 samples, including fecal (<i>n</i> = 206), plasma (<i>n</i> = 206), and peripheral blood mononuclear cell (PBMC) samples (<i>n</i> = 187), were collected from 443 individuals with RA, systemic lupus erythematosus, and controls. Fecal, plasma and PBMC samples were subjected to 16S rRNA sequencing, liquid chromatography-tandem mass spectrometry, RNA sequencing and 4D DIA proteomics, respectively. A collagen-induced arthritis mouse model was used to investigate the role of the metabolite conjugated linoleic acid (CLA) in experimental arthritis. An RA clinical cohort (<i>n</i> = 26) was recruited to validate the potential role of CLA as an adjunct to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) therapy.</p> Results <p>Multi-omics analysis revealed comprehensive alterations in metabolic signatures (metabolism-related molecules, metabolites, and metabolic pathways) in RA. Lipid metabolism pathways, particularly linoleic acid metabolism, appear to play a significant regulatory role in RA progression. Metabolites and molecules involved in linoleic acid metabolism were significantly associated with clinical phenotypes in RA patients. In animal experiments, CLA reduced arthritis scores, swollen joint counts, histopathological scores, and inflammatory levels. Finally, CLA supplementation accelerated the reduction of inflammatory levels in RA patients receiving csDMARDs therapy.</p> Conclusion <p>These findings reveal lipid metabolism as a druggable axis, position dietary CLA as an adjunct to improve outcomes in RA, and offer a new avenue to enhance remission rates.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lipid metabolism dysregulation in rheumatoid arthritis: from multi-omics discovery to adjunctive therapy with conjugated linoleic acid

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Jianghua Chen,
  • Zhuming Yin,
  • Wantai Dang,
  • Congcong Jian,
  • Tingting Wang,
  • Jiaxin Huang,
  • Xiaoting Zhu,
  • Yuanli Wei,
  • Jing Gao,
  • Jie Zhang,
  • Jiang Su,
  • Jing Zhu,
  • Jianhong Wu,
  • Qinghua Zou,
  • Pilei Si,
  • Fanxin Zeng

摘要

Objective

This study aims to comprehensively analyze the role of metabolic signatures in rheumatoid arthritis (RA).

Methods

A total of 599 samples, including fecal (n = 206), plasma (n = 206), and peripheral blood mononuclear cell (PBMC) samples (n = 187), were collected from 443 individuals with RA, systemic lupus erythematosus, and controls. Fecal, plasma and PBMC samples were subjected to 16S rRNA sequencing, liquid chromatography-tandem mass spectrometry, RNA sequencing and 4D DIA proteomics, respectively. A collagen-induced arthritis mouse model was used to investigate the role of the metabolite conjugated linoleic acid (CLA) in experimental arthritis. An RA clinical cohort (n = 26) was recruited to validate the potential role of CLA as an adjunct to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) therapy.

Results

Multi-omics analysis revealed comprehensive alterations in metabolic signatures (metabolism-related molecules, metabolites, and metabolic pathways) in RA. Lipid metabolism pathways, particularly linoleic acid metabolism, appear to play a significant regulatory role in RA progression. Metabolites and molecules involved in linoleic acid metabolism were significantly associated with clinical phenotypes in RA patients. In animal experiments, CLA reduced arthritis scores, swollen joint counts, histopathological scores, and inflammatory levels. Finally, CLA supplementation accelerated the reduction of inflammatory levels in RA patients receiving csDMARDs therapy.

Conclusion

These findings reveal lipid metabolism as a druggable axis, position dietary CLA as an adjunct to improve outcomes in RA, and offer a new avenue to enhance remission rates.